Compare · IMDX vs NEOG
IMDX vs NEOG
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.65B, about 29.0x IMDX ($91.3M).
- NEOG has been more active in the news (17 items in the past 4 weeks vs 3 for IMDX).
- NEOG has more recent analyst coverage (6 ratings vs 0 for IMDX).
- Company
- Insight Molecular Diagnostics Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- $91.3M
- $2.65B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1989
- News (4w)
- 3
- 17
- Recent ratings
- 0
- 6
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest IMDX
- iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
- iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
- Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
- SEC Form S-8 filed by Insight Molecular Diagnostics Inc.
Latest NEOG
- SEC Form 4 filed by Neogen Corporation
- Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
- SEC Form 10-Q filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
- Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
- NEOG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Neogen (NEOG)
- Director Woteki Catherine E was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 51% to 28,921 units (SEC Form 4)
- Director Wainer Andrea F was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 483% to 11,834 units (SEC Form 4)